[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gynecologic-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gynecologic-cancer":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,78,0,25,[9,52,75,98,127,151,188,215,249,272,298,330,352,377,399,420,443,464,495,524,551,575,601,630,678],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":35,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100633240","study-of-high-precision-evaluation-of-molecular-residual-disease-through-a-platform-for-cancer-tracking-and-interception-sherlock-100633240",false,"NCT07524114","Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)","SHERLOCK","Inclusion Criteria:\n\n1. Patients with histopathological confirmation of cancer. Patients whose diagnosis are made by cytology may also be considered for this study. For tumor types that are typically diagnosed using unequivocal imaging findings or biomarker profiles (e.g. hepatocellular cancer, uveal melanoma), they can be eligible without histopathological or cytological confirmation.\n2. Patients must have cancer that is planned for or has undergone curative intent treatment (e.g. surgery, definitive radiation, definitive chemoradiation, adjuvant radiation, adjuvant chemotherapy, adjuvant chemoradiation, etc). Curative intent treatment must be completed within 12 months of study entry. For patients on adjuvant\u002Fmaintenance endocrine or biological therapy (e.g. bevacizumab, immunotherapy, etc), enrollment within 12 months of completion of curative intent treatment is allowed.\n3. Patient must be ≥ 18 years old.\n4. All patients must have signed and dated an informed consent form.\n\nExclusion Criteria:\n\n1\\. History of another active invasive cancer within 2 years prior to study enrolment. Exceptions include squamous and basal cell carcinoma of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the investigator, is considered cured with minimal risk of recurrence within 2 years.","ALL","18 Years",{"count":20,"type":21},7000,"ESTIMATED","OBSERVATIONAL","This study will collect, annotate, and sequence biospecimens (blood, tissue, urine, saliva and surgery drainage) from patients across different cancer types to detect molecular residual disease (MRD). Imaging scans and clinical data will also be gathered. This will allow for early cancer interception, and hopefully prolong relapse-free survival across tumor types. Results of ctDNA testing will be provided for clinical decisions and to determine eligibility for other linked interventional interception therapeutic studies, each of which will have a separate protocol.",[25,26,27,28,29,30,31,32,33,34],"Breast Cancer","Lung Cancer","Melanoma","Gynecologic Cancer","Genitourinary Cancer","Pancreatobiliary Cancer","Gastrointestinal Cancer","Head and Neck Cancer","Rare Cancer","Unknown Primary Tumors",[36,37,38],"Minimal Residual Disease","Liquid Biopsy","Circulating Tumor DNA","RECRUITING","2026-08-19",{"date":42,"type":43},"2026-08-21","ACTUAL",{"date":45,"type":43},"2026-03-31",{"date":47,"type":21},"2031-03-31",{"name":49,"class":50},"University Health Network, Toronto","OTHER",1,{"id":53,"slug":54,"hasResults":12,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":51},"100651823","exercise-oncology-clinic-pilot-feasibility-trial-100651823","NCT07765927","Exercise Oncology Clinic Pilot Feasibility Trial","Pilot Feasibility Trial for the Exercise Oncology Clinic in Breast and Gynecologic Oncology Patients","Inclusion Criteria:\n\n* Age ≥18 years\n* Confirmed diagnosis of breast or gynecologic cancer (any stage)\n* Willingness to participate in the exercise oncology program and associated research procedures Ability to provide informed consent\n* Clearance to participate in exercise as determined by completion of the Physical Activity Readiness Questionnaire Plus (PAR-Q+) and any additional clinical screening as needed\n\nExclusion Criteria:\n\n* Presence of absolute contraindications to exercise (e.g., unstable cardiovascular disease, acute illness, or other conditions that preclude safe participation in physical activity)\n* Determination by a referring or treating healthcare provider that the patient is not appropriate for exercise participation at the time of screening\n* Inability to complete required screening procedures, including the PAR-Q+",{"count":60,"type":21},30,"INTERVENTIONAL",[63],"NA","The purpose of this pilot study is to test a supervised exercise program for adults with a history of breast or gynecologic cancer to see if it is safe, helpful, and easy to take part in.",[25,28],"2026-08-10",{"date":68,"type":43},"2026-08-14",{"date":70,"type":43},"2026-08-03",{"date":72,"type":21},"2027-04-15",{"name":74,"class":50},"Jess S. Gorzelitz",{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":61,"phases":84,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":51},"100604582","phase-2-the-use-of-guarana-to-treat-fatigue-in-patients-with-neuroendocrine-tumors-and-gynecologic-cancers-guarana-fatigue-100604582","NCT07151391","The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue)","The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers","Inclusion Criteria:\n\n* Subjects aged ≥ 18 years.\n* Cohort A (Neuroendocrine Tumor) Only:\n\n  ---Subjects with unresected locally advanced or metastatic well differentiated neuroendocrine tumors who are either on a watch- and-wait approach or receiving treatment with somatostatin analog(s). Patient who received and completed another active treatment but are on a \"break\" from treatment will be allowed to enroll (e.g., patients that had completed PRRT).\n* Cohort B (Gynecological Cancer) Only:\n\n  ---Subjects with early-stage (I or II) ovarian\u002Ffallopian-tube cancer in surveillance who have completed all treatment or are receiving adjuvant treatment.\n* Or\n\n  ---Subjects with endometrial cancer which is low risk, low-intermediate risk in surveillance, or high-intermediate risk receiving brachytherapy. Risk category is based on GOG criteria.\n* ECOG Performance Status ≤ 2.\n* Documentation of a score of 4 or higher when answering either of the NCCN-recommended screening questions (\"How exhausted do you feel on a scale of 0 to 10?\" or \"How impaired do you feel by this fatigue on a scale of 0 to 10?\") within 4 weeks prior to randomization\n* Adequate organ function as defined as:\n\n  * Hematologic:\n\n    * Hemoglobin ≥ 9 g\u002FdL\n  * Hepatic:\n\n    * Total Bilirubin ≤ 1.5x institutional upper limit of normal (ULN) or ≤3 x ULN with documented liver involvement and\u002For Gilbert's disease\n    * AST(SGOT)\u002FALT(SGPT) ≤ 3 × institutional ULN ----Subjects with liver metastases will be allowed to enroll with AST and ALT levels ≤ 5 x ULN.\n  * Renal:\n\n    ---Estimated creatinine clearance ≥ 30 mL\u002Fmin by Cockcroft-Gault formula\n  * For female subjects: Negative pregnancy test or evidence of post-menopausal status. The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause or having undergone surgical sterilization (bilateral oophorectomy or hysterectomy). The following age-specific requirements apply:\n\n    * Women \\\u003C 50 years of age:\n\n      ----Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution; or\n\n      ----Underwent surgical sterilization (bilateral oophorectomy or hysterectomy).\n    * Women ≥ 50 years of age:\n\n      * Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments and luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution; or Amenorrhea for 24 months following cessation of all exogenous hormonal treatments, if applicable; or\n      * Had radiation-induced menopause with last menses \\>1 year ago; or\n      * Had chemotherapy-induced menopause with last menses \\>1 year ago; or\n      * Underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).\n  * Female subjects of childbearing potential and male subjects with a sexual partner of childbearing potential must agree to use a highly effective method of contraception.\n  * Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.\n\nExclusion Criteria:\n\n* For the Neuroendocrine Tumor cohort: Receiving treatment with Cytotoxic Chemotherapy, Radiation Therapy, PRRT or TKIs within 6 weeks prior to the first dose of study treatment.\n* For the Gynecological Cancer cohort: Receiving any systemic treatment besides those listed in Inclusion 3-Cohort B (Gyn only) within 6 weeks prior to the first dose of study treatment.\n* Untreated or uncontrolled endocrinopathy which is likely to significantly impact study participation.\n* History of significant autoimmune disease in the opinion of the investigator that is likely to significantly impact study participation.\n* Prior use of guarana supplements within two months of consent.\n* Self-reported \"caffeine sensitivity\" defined as excessive unwanted feelings of anxiousness, jitteriness, difficulty sleeping, or anxiety after caffeine exposure, which in the opinion of the Investigator is likely to negatively impact study participation.\n* Concurrent use of psychostimulants (e.g., lisdexamfetamine, methylphenidate).\n* Major surgery within 4 weeks prior to starting study therapy or subjects who have not fully recovered from major surgery.\n* The diagnosis of another malignancy which, in the opinion of the investigator, is likely to negatively impact subject safety or study aims.\n* Known brain metastases or cranial epidural disease.\n\n  --Note: Subjects with brain metastases or cranial epidural disease adequately treated with radiotherapy and\u002For surgery and stable for at least 4 weeks before the first dose of study treatment will be allowed on trial. Subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of the first dose of study treatment.\n* Current evidence of uncontrolled, significant intercurrent illness including, but not limited to, the following conditions:\n\n  --Cardiovascular disorders:\n  * Significant symptomatic carcinoid heart disease in the opinion of the investigator\n  * Congestive heart failure New York Heart Association Class III or IV, unstable angina pectoris, serious cardiac arrhythmias.\n  * Stroke (including transient ischemic attack \\[TIA\\]), myocardial infarction (MI), or other ischemic events) within 3 months before the first dose.\n  * Thromboembolic events (eg, deep venous thrombosis, pulmonary embolism) within 1 month before the first dose.\n  * QTc prolongation defined as a QTcF \\> 500 ms.\n  * Known congenital long QT.\n  * Uncontrolled hypertension per investigator assessment or grade 3 hypertension per CTCAE v.5.0\n  * Any other condition that would, in the Investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures (e.g., infection\u002Finflammation, intestinal obstruction, unable to swallow medication, \\[subjects may not receive the therapy through a feeding tube\\], social\u002F psychological issues, etc.)\n* Known HIV infection with a detectable viral load within 6 months of the anticipated start of treatment.\n\n  --Note: Subjects on effective antiretroviral therapy with an undetectable viral load within 6 months of the anticipated start of treatment are eligible for this trial.\n* Known active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination, radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), or hepatitis C.\n\n  --Note: Subjects with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \\[anti-HBc\\] and absence of HBsAg) are eligible. Subjects positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.\n* Medical, psychiatric, cognitive, or other conditions that may compromise the subject's ability to understand the subject information, give informed consent, comply with the study protocol or complete the study.\n* Known hypersensitivity or allergy to investigational product (IP).\n* Subjects taking prohibited medications as described in Section 6.6.2 or medications for which caffeine intake is contraindicated including: β-adrenergic agonists, and\u002For medications that contain pseudoephedrine. A washout period of prohibited medications for a period of at least five half-lives or as clinically indicated should occur before the start of treatment.",{"count":83,"type":21},86,[85],"PHASE2","The purpose of this clinical trial is to learn if the drug guarana improves symptoms of fatigue in patients with neuroendocrine tumors and gynecologic cancers",[88,28],"Neuroendocrine Tumors","2026-08-05",{"date":91,"type":43},"2026-08-07",{"date":93,"type":43},"2025-09-03",{"date":95,"type":21},"2028-09",{"name":97,"class":50},"University of Utah",{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":12,"sex":106,"minAge":18,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":61,"phases":110,"briefSummary":111,"conditions":112,"keywords":113,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":51},"100631551","massage-oncology-pain-anxiety-feasibility-100631551","NCT07502157","Massage, Oncology, Pain, Anxiety, Feasibility","The Impact of Massage Therapy on Pain and Anxiety of Patients With Gynecologic Cancer While Receiving Infusion Treatment (IMPACT)","IMPACT","Inclusion Criteria:\n\n* Patients with gynecologic cancer receiving active treatment of infusion, including but not limited to chemotherapy, immunotherapy, antibiotics, and blood.\n* Patients with gynecological cancer undergoing an infusion for the first time.\n\nExclusion Criteria:\n\n* Patient with gynecologic cancer that has received infusion therapy anytime within the past 2 years.","FEMALE","85 Years",{"count":109,"type":21},24,[63],"The goal of this clinical trial is to determine the feasibility of studying massage therapy in patients with gynecologic cancers while receiving infusion treatments. The central hypothesis is that it is feasible to implement a massage intervention study in an infusion center at an academic hospital, and measure pain and anxiety in patients with gynecological cancer. The main questions it aims to answer are:\n\nCan investigators evaluate feasibility to conduct a study from a design standpoint? Can investigators assess the use of randomization, blinding of assessors, potential to control the study with an attention group, and recruitment\u002Fretention processes? Can investigators successfully collect outcome measures of pain and anxiety, pre\u002Fpost intervention? Researchers will investigate degree of resources needed, such as massage therapists, assessors, and timing of delivery intervention. Assess positive\u002Fnegative effects on target population determining massage modality and anatomical location. Researchers will compare massage therapy to an attention control group, to see if massage therapy works to treat pain and anxiety in patients with cancer.\n\nEstablish variability in outcome measures.\n\nParticipants will:\n\nBe randomized and receive either massage therapy or attention control over the course of three consecutive infusion therapy treatments. Each infusion therapy treatment occurs every 2-4 weeks.",[28],[114,115,116,117,118],"Massage therapy","Pain","Anxiety","Cancer","Feasibility","2026-07-31",{"date":70,"type":43},{"date":122,"type":21},"2026-08",{"date":124,"type":21},"2026-12",{"name":126,"class":50},"Jill Cole",{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":12,"sex":106,"minAge":18,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":61,"phases":137,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":150},"100573449","activity-coaching-during-pelvic-radiation-therapy-100573449","NCT06746428","Activity Coaching During Pelvic Radiation Therapy","ACTIVATE: A Pilot Randomized Activity Coaching Trial to Increase Vitality and Energy During Post-operative Pelvic Radiation Therapy for Endometrial Cancer","ACTIVATE","Inclusion Criteria:\n\n* At least 18 years of age\n* Pathologic diagnosis of endometrial cancer (any histology, Stage I-IVA)\n* Has undergone modified radical or radical hysterectomy\n* Plan to receive adjuvant treatment with pelvic external beam radiation therapy at ISCI\n* ECOG performance status of 0-1\n* Patient has a computer, smart phone, or tablet virtual access to the web-based platform and email\n* Able to read, understand and provide written informed consent\n* Deemed appropriate for unmonitored exercise by treating physician based on the following evidence-based criteria (1)\n\n  * Walk without any assistance or assistance device\n  * Absence of significant cognitive impairment\n  * Absence of high risk for falls\n* Participant does not need to refrain from any activity\n\nExclusion Criteria:\n\n* Unable to schedule and attend coaching visits\n* Participation in a regular exercise program of ≥150 minutes of moderate intensity exercise a week at baseline\n* Unable to perform the five-times stand test\n* Medical comorbidities including:\n\n  * Unstable angina\n  * Uncontrolled dysrhythmias\n  * Acute pulmonary embolus\n  * Active pulmonary infection",{"count":136,"type":21},16,[63],"Research has shown that for women who are undergoing pelvic radiation therapy, fatigue is a common side effect. Fatigue that occurs during radiation therapy can make it harder to perform daily living activities. While there are studies that recommend exercise as a treatment for fatigue in cancer patients and survivors, there are currently no studies that focus on the role of exercise for women undergoing pelvic radiation therapy. The purpose of this study is to see if incorporating an activity coaching program is helpful in improving treatment-related fatigue for women undergoing pelvic radiation therapy for endometrial cancer.",[140,28,141],"Radiation Therapy","Exercise Therapy","2026-07-30",{"date":70,"type":43},{"date":145,"type":43},"2025-01-27",{"date":147,"type":21},"2027-01-01",{"name":149,"class":50},"Inova Health Care Services",4,{"id":152,"slug":153,"hasResults":12,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":61,"phases":161,"briefSummary":162,"conditions":163,"keywords":173,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":51},"100596191","the-florida-ascent-study-100596191","NCT07042243","The Florida ASCENT Study","The Florida Partnership for Adding Social Context to Address Cancer Survivorship Outcomes (Florida ASCENT)","Patient Eligibility Inclusion Criteria:\n\n1. ≥18 years old.\n2. Pathologically confirmed diagnosis, with a focus on, but not limited to, colorectal, prostate, lung, breast, gynecologic, hematologic, or skin (including melanoma) cancers.\n3. Self-reported ability to read and speak English.\n4. Able to provide informed consent.\n\nPatient Eligibility Exclusion Criteria:\n\n1. ≤18 years old.\n2. Does not have a pathologically confirmed diagnosis of cancer.\n3. Currently receiving active cancer treatment (e.g., active chemotherapy, radiation therapy or stem cell transplant); patients on stable maintenance therapy are eligible (e.g., endocrine therapy, targeted therapy, or select immunotherapy).\n\n3\\) Does not live within the state of Florida. 3) Does not self-reported ability to read and speak English or Spanish. 4) Not able to provide informed consent.\n\nProvider Eligibility Inclusion Criteria\n\n1. ≥18 years old.\n2. Currently works as a physician, physician assistant, patient navigator and\u002For health system\u002Fadministrative leader in UF and UM affiliated clinics.\n3. Self-reported ability to read and speak English or Spanish.\n4. Able to provide informed consent.\n\nProvider Eligibility Exclusion Criteria\n\n1. ≤ 18 years old.\n2. Does not currently works as a physician, physician assistant, patient navigator and\u002For health system\u002Fadministrative leader in UF and UM affiliated clinics.\n3. Does not self-report having the ability to read and speak English.\n4. Not able to provide informed consent.","100 Years",{"count":160,"type":21},100,[63],"The goal of this clinical trial is to adapt, implement, and evaluate MyCarePulse and ASCENT patient navigator to overcome barriers to care among patients with cancer.\n\nThe main hypotheses it aims to test are:\n\n* At the patient level, the intervention will result in higher levels of food security, self- efficacy for dietary behaviors, and higher diet quality than standard care.\n* At the provider level, the intervention will be feasible, acceptable, appropriate, and able to enhance individualized care for patient wellness.\n\nResearchers will compare cancer patients receiving the MyCarePulse and ASCENT patient navigator intervention to those receiving standard care, to see if the intervention improves food security, self-efficacy, and diet quality.\n\nPhase 1\n\nPatient Participants will:\n\n* Complete the ASCENT Questionnaire, which is comprised of the following:\n\n  * U.S. Food Security Survey Module (U.S. FSSM)\n  * Patient-Reported Outcomes Measurement Information System (PROMIS-29)\n  * General Self-Efficacy Scale (GSE)\n* Complete the Automated Self-Administered 24-Hour (ASA24®) Dietary Assessment Tool a total of 4 times.\n* Be assessed using the Veggie Meter instrument\n* Participate in two semi-structured interviews\n\nProvider Participants will:\n\n•Participate in one semi-structured interview\n\nPhase 2\n\nPatient Participants will:\n\n* Participate in ASCENT patient navigator screenings and consultations\n* Complete the ASCENT Questionnaire, which comprises the U.S. FSSM, PROMIS-29, and ASA24®",[117,164,165,166,167,168,26,25,28,169,170,27,171,172],"Food Deprivation","Food Habits","Food Selection","Colorectal Cancer","Prostate Cancer","Hematologic Cancer","Skin Cancer","Nutrition Poor","Nutritional Deficiency",[174,117,175,176,177,178],"Food Insecurity","Food Access","Community-Informed Research","Nutritional Needs","Mixed-Methods","2026-07-21",{"date":181,"type":43},"2026-07-23",{"date":183,"type":43},"2025-12-05",{"date":185,"type":21},"2027-08",{"name":187,"class":50},"University of Florida",{"id":189,"slug":190,"hasResults":12,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":12,"sex":106,"minAge":18,"maxAge":196,"enrollmentInfo":197,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":199,"conditions":200,"keywords":4,"overallStatus":205,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":4},"100645681","intraoperative-microscopic-assessment-of-lymph-node-status-in-gynecological-malignancies-100645681","NCT07702721","Intraoperative Microscopic Assessment of Lymph Node Status in Gynecological Malignancies","Intraoperative Microscopic Assessment of Lymph Node Status in Gynecological Malignancies Using Full-Field Optical Coherence Tomography and Dynamic Cell Imaging: A Step From Image Guided Surgery Towards Deep Learning Applications","IMAGINE","Inclusion Criteria:\n\n* Women undergoing surgery for gynecological malignancies (ovarian, endometrial, cervical and vulvar cancer)\n* Need for sentinel lymph nodal excision (staging)\n* Need for lymph nodal dissection (staging\u002F cytoreductive reasons)\n* 18-99 years old\n* Absence of contemporary lymphatic diseases\n* Absence of previous oncological disease in the last 5 years\n\nExclusion Criteria:\n\nPresence of lymphoproliferative or granulomatous diseases affecting lymph nodes\n\n* Active systemic infection or inflammatory conditions influencing lymph node architecture\n* Poor-quality lymph node specimens (necrotic, damaged, or with significant optical artifacts)\n* Inadequate histopathological reference standard or inability to correlate imaging with histology\n* Failure of sentinel lymph node mapping or non-standardized surgical procedures\n* Prolonged ischemia time or improper specimen handling prior to imaging (\\>30 mins)","99 Years",{"count":198,"type":21},160,"The IMAGINE study is a monocentric, observational, prospective study evaluating the diagnostic performance of Full-Field Optical Coherence Tomography (FF-OCT) combined with Dynamic Cell Imaging (DCI) (Van Gogh System, AQUYRE Biosciences) for the intraoperative detection of lymph node metastases in fresh, unstained, ex vivo specimens from women undergoing surgery for gynecological malignancies (ovarian, endometrial, cervical, and vulvar cancer).\n\nThe primary objective is to assess the sensitivity, specificity, accuracy, negative predictive value, and positive predictive value of FF-OCT\u002FDCI in detecting macrometastases (\\>2 mm), micrometastases (\\\u003C2 mm), and isolated tumor cells (\\\u003C0.2 mm), using hematoxylin-eosin histopathology as the reference standard, with results reported at both the lymph-node and patient level in accordance with STARD guidelines. Secondary objectives include determining the minimum detectable metastatic focus size, developing an FF-OCT\u002FDCI imaging atlas of normal and metastatic lymph nodes, and developing a deep-learning algorithm for automated intraoperative assessment of lymph node status.\n\nBased on an estimated 10% prevalence of nodal metastasis, a sample of 351 lymph nodes (approximately 160 patients) will be enrolled - prospectively at Fondazione Policlinico Universitario A. Gemelli IRCCS, and retrospectively from patients previously enrolled in the PROVE study (from February 2026) - over a planned study duration of 36 months.",[28,201,202,203,204],"Cervical Cancer","Endometrial Cancer","Ovary Cancer","Vulvar Cancer","NOT_YET_RECRUITING","2026-07-13",{"date":208,"type":43},"2026-07-14",{"date":210,"type":21},"2026-08-01",{"date":212,"type":21},"2029-08-01",{"name":214,"class":50},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":4,"eligibilityCriteria":221,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":61,"phases":224,"briefSummary":225,"conditions":226,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":51},"100560657","phase-2-repurposing-riluzole-for-cancer-related-cognitive-impairment-a-pilot-trial-100560657","NCT06580002","Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial","Repurposing Riluzole for Augmenting Brain-Derived Neuropathic Factor (BDNF) Levels and Cognitive Function in Patients Experiencing Cancer-Related Cognitive Impairment: An Interventional Pilot Clinical Trial","Inclusion Criteria:\n\n1. Cohort-specific inclusion for male and female patients.\n\n   a. Cohort A (no prior cranial radiation) i. Diagnosed with one of the following:\n   * Breast cancer exposed to treatment including chemotherapy, radiotherapy, surgery and\u002For other breast cancer interventions.\n   * Non-breast cancer patients exposed to anthracyclines- or platinum-containing chemotherapy within the past 3 years.\n   * Non-breast cancer patients exposed to other anticancer therapies within the past 3 years.\n\n     b. Cohort B (prior cranial radiation)\n   * Previously received radiotherapy or radiosurgery to the brain for benign, malignant, or metastatic tumors.\n   * Life expectancy \\> 6 months\n2. Washout from investigational and conventional interventions is up to the discretion of the investigator. Concurrent participation in another intervention is allowable if judged by the Principal Investigator that this would not be scientifically or medically incompatible with this study.\n3. ≥18 years of age\n4. Perceived by patient or investigator that cognitive function has worsened since receipt of cranial radiation or cancer treatment.\n5. Able to provide informed consent.\n6. Literacy in English, Chinese, Korean, Vietnamese, or Spanish, to complete the questionnaires.\n7. Patients must agree to complete and be able to complete the questionnaires and computerized assessments used to measure functional outcomes.\n\n   * Note: Patients who have visual impairment or have degenerative conditions (e.g. Parkinsons's disease, etc.) can participate if they cannot complete computerized assessments, as long as they can still complete the questionnaires with assistance.\n\nExclusion Criteria:\n\n1. Cohort-specific exclusion for male and female patients:\n\n   1. Cohort A (no prior cranial radiation)\n\n      * History of or current presence of primary brain tumors or brain metastases.\n   2. Cohort B (prior cranial radiation)\n\n      * Diagnosed with high grade glioma.\n2. Unwilling to undergo neuropsychological assessments necessary for the study.\n3. Women who are breastfeeding, pregnant or are planning to get pregnant during the study period. Persons of child-bearing potential (POCBP) must have a negative pregnancy test at screening if there is suspicion of pregnancy.\n\n   a. Female patients who are considered not to be of childbearing potential must have a history of being postmenopausal (with a minimum of 1 year without menses), tubal ligation, or hysterectomy.\n4. History of suspected hypersensitivity to riluzole or to any of its excipients.\n5. Patients taking or planned to take medications\u002Fsubstances with potential drug-drug interactions: pixantrone, current smoker (defined as having smoked within the last month), abametapir, cannabis, capmatinib, lapatinib, methotrexate, and levoketoconazole.\n6. Hepatic impairment as indicated by: AST or ALT ≥ 3x upper limit normal (ULN)\n7. Have serious pre-existing medical conditions that, in the judgment of the investigator, would preclude participation in this study.",{"count":223,"type":21},75,[85],"This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor (BDNF) levels in cancer survivors (recently completing prior treatment regimens) or patients who have received whole brain radiation for benign or malignant tumors with cancer related cognitive impairment.",[25,227,228,26,32,167,229,230,29,28,231,232,233,234,168,235,236,237,238,27,239,240],"Sarcoma","Gastric Cancer","Ovarian Cancer","Liver Cancer","Urinary Bladder Cancer","Leukemia","Lymphoid Leukemia","Myeloma Multiple","Pancreas Cancer","Non-hodgkin Lymphoma","Hodgkin Lymphoma","Brain Cancer","Mycosis Fungoides","Kidney Cancer","2026-07-11",{"date":208,"type":43},{"date":244,"type":43},"2024-12-02",{"date":246,"type":21},"2027-12",{"name":248,"class":50},"University of California, Irvine",{"id":250,"slug":251,"hasResults":12,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":12,"sex":106,"minAge":18,"maxAge":4,"enrollmentInfo":256,"targetDuration":4,"studyType":61,"phases":258,"briefSummary":259,"conditions":260,"keywords":261,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":51},"100643492","cs-131ldr-brachytherapy-for-organ-preserving-irradiation-for-recurrent-cervical-and-endometrial-cancer-100643492","NCT07631572","Cs-131LDR Brachytherapy for Organ-Preserving Irradiation for Recurrent Cervical and Endometrial Cancer","Phase II Clinical Trial of Cesium-131 Low-dose Rate Interstitial Brachytherapy as an Organ-preserving Irradiation Technique for Recurrent Cervical and Endometrial Cancer","Inclusion Criteria:\n\n* Patients must have histologically or cytologically confirmed vaginal recurrence of endometrial (endometrioid adenocarcinoma, uterine serous, carcinosarcoma, clear cell) or cervical (squamous, adenosquamous, or adenocarcinoma) cancer and prior history of pelvic radiation.\n* Patients must have vaginal recurrence that is amenable to cesium implant for salvage\n* Patients must have a vaginal lesion that is measurable according to RECIST 1.1 criteria; that is, at least 1 cm upon measurement by CT, or MRI if the patient cannot have a CT with contrast or lesion is not visualized on CT scan, or measurement by calipers if the lesion is not seen on CT or MRI.\n* Patients must have previous external beam radiation treatment to the pelvis for the uterine cervix or endometrial malignancy that has recurred to be eligible for this study, so long as the prior exposure does not exceed tolerance at the discretion of the treating physician.\n* Gynecologic Oncology Group performance status of 0, 1, or 2 (see Appendix A).\n* There are no minimum organ\u002Fmarrow function requirements because patients will not be receiving systemic therapy.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Patients who have another concurrent, active invasive malignancy or have had a prior invasive malignancy diagnosed within the last three years, with the following two exceptions: \\[a\\] non-melanoma skin cancer and\u002For \\[b\\] prior in situ carcinoma of the cervix and\u002For \\[c\\] in situ bladder cancer.\n* Patients who have metastatic or regional lymph node metastases who have radiographic evidence of disease at time of study enrollment. Patients who have had metastasis or lymph nodes previously treated without radiographic disease at time of study enrollment may be considered at discretion of the treating radiation oncologist.\n* Receipt of epoetin alpha (Procrit, Epogen) within 1 month of study screening.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to Cesium-131 implant or other agents used in this study.\n* Pregnant women are excluded from this study because radiation is a known teratogen. Patient must agree to use two forms of birth control if they are of child-bearing potential. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, throughout duration of active treatment and for two months after completion of radiation. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately.",{"count":257,"type":21},10,[63],"This clinical trial studies how well cesium-131 low-dose rate interstitial brachytherapy works as an organ-preserving radiation technique in the treatment of patients with cervical and endometrial cancer that has come back in the vagina after a period of improvement following pelvic radiation therapy (vaginal recurrence). In cervical and endometrial cancer patients with vaginal recurrence following pelvic radiation therapy, the only curative option involves a major surgical procedure which removes all the contents of the pelvic cavity, such as the uterus, cervix, bladder, rectum, vagina, and vulva. This procedure is complex and comes with many side effects; therefore, a need remains to improve radiation treatment techniques so radiation therapy can be offered as an alternative treatment option for these patients. Cesium-131 low-dose rate interstitial brachytherapy is a form of internal radiation therapy called brachytherapy. It uses grain-of-rice-sized radioactive seeds implanted directly into or near where the tumor has returned. The implanted seeds give off radiation to kill tumor cells for only a short time after they are placed. Most of the radiation is gone within a few weeks. The seeds stay in the body permanently, but they become inactive quickly. Cesium-131 low-dose rate interstitial brachytherapy may be an effective organ-preserving radiation technique for the treatment of cervical and endometrial cancer patients with vaginal recurrence following pelvic radiation therapy",[28],[262],"Cesium","2026-07-08",{"date":265,"type":43},"2026-07-10",{"date":267,"type":21},"2026-07",{"date":269,"type":21},"2030-05",{"name":271,"class":50},"Denise Fabian",{"id":273,"slug":274,"hasResults":12,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":61,"phases":281,"briefSummary":282,"conditions":283,"keywords":284,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":297},"100615767","care-tool-study-aim-3-100615767","NCT07296887","CARE Tool Study Aim 3","Implement and Evaluate the CARE Tool in a Randomized Trial","Inclusion Criteria for Implementation champions:\n\n\\- Members of the cancer care team (e.g., physicians, nurses, research coordinators, financial navigators, social workers) that work with patients receiving treatment for gynecologic, lung, prostate, or colorectal cancer; or members of the billing team and employee of Siteman Cancer Center, Barnes Jewish Hospital, Washington University, Delbert Day Cancer Institute at Phelps Health, or Alton Memorial Hospital\n\nExclusion Criteria for Implementation champions:\n\n* Implementation champions are ineligible if they are non-employees of Siteman Cancer Center, Barnes Jewish Hospital, Washington University, Delbert Day Cancer Institute at Phelps Health, or Alton Memorial Hospital\n* Do not treat patients for gynecologic, prostate, lung, or colorectal cancer\n\nInclusion Criteria for Patients:\n\n* Age 18 and over\n* Primary or recurrent diagnosis of gynecologic, prostate, lung, or colorectal cancer in the last 12 months\n* Receiving cancer treatment from Siteman Cancer Center, Delbert Day Cancer Institute at Phelps Health, or Alton Memorial Hospital\n* Self-reported ability to read and speak English\n\nExclusion Criteria for Patients:\n\n* Under the age of 18\n* Not diagnosed with gynecologic, prostate, lung, or colorectal cancer within the previous 12 months from recruitment\n* Not receiving care at Siteman Cancer Center, Delbert Day Cancer Institute at Phelps Health, or Alton Memorial Hospital\n* Cannot give consent due to cognitive or emotional barriers",{"count":280,"type":21},430,[63],"This study is a multi-site randomized trial to study the implementation of the CARE Tool and evaluate the CARE Tool. The CARE Tool is a web-based tool that gives people information about cancer care costs, health insurance, and resources to help with costs. Overall, the study aims to help patients with cancer overcome barriers they face navigating insurance and accessing financial resources.",[28,168,26,167],[285,286,117,287,288],"Insurance","Insurance coverage","Cost of medical care","Financial toxicity","2026-07-06",{"date":263,"type":43},{"date":292,"type":43},"2026-04-08",{"date":294,"type":21},"2028-07-31",{"name":296,"class":50},"Washington University School of Medicine",3,{"id":299,"slug":300,"hasResults":12,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":304,"eligibilityCriteria":305,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":306,"targetDuration":4,"studyType":61,"phases":308,"briefSummary":309,"conditions":310,"keywords":315,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":323,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":329},"100443348","a-study-evaluating-the-integrative-medicine-at-home-imhome-program-in-people-with-cancer-100443348","NCT05053230","A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer","Integrative Medicine for Patient-reported Outcomes, Values, and Experience (IMPROVE)","IMPROVE","Inclusion Criteria:\n\n* Age ≥ 18 years or older\n* Karnofsky score 60 or greater\n* Life expectancy greater than six months\n* English speaking\n\nAdditional Inclusion Criteria for Head and Neck, Thoracic, Gynecologic, Melanoma and Breast Baskets\n\n* Patients with a diagnosis of head and neck tumors, thoracic tumors, gynecological tumors, melanoma, breast cancer, or gynecologic cancer\n* Actively receiving systemic oncological treatment or radiotherapy, or within 4 weeks of radiotherapy completion or primary cytoreductive surgery\n* Worst fatigue over the last 7 days rated 4 or greater on (0-10 scale)\n\nAdditional Inclusion Criteria for First Remission Gynecologic Cancer Basket\n\n* Patients with a diagnosis or clinical suspicion of gynecologic malignancy who have completed definitive first line treatment (maintenance hormonal or targeted therapies are allowed)\n\nAdditional Inclusion Criteria for the Advanced Cancer Basket:\n\n* Patients with a diagnosis of Stage III or IV lung cancer; any stage pancreatic cancer, unresectable cholangiocarcinoma, unresectable liver cancer, unresectable ampullary or peri-ampullary cancer, or other stage IV gastrointestinal cancer; stage III or IV ovarian or fallopian tube cancers or other stage IV gynecologic cancer; stage IV breast cancer; stage III testicular cancer or any stage IV genitourinary cancer; stage IV sarcoma; stage IV melanoma; stage IV endocrine cancer; lymphoma, myeloma, or Leukemia\n* Actively receiving oncological treatment, radiotherapy or active surveillance\n\nAdditional Inclusion Criteria for the Cancer Survivor Basket:\n\n* Completed active cancer treatment (e.g., surgery, radiation, chemotherapy) (maintenance hormonal or targeted therapies are allowed).\n* Worst fatigue over the last 7 days rated 4 or greater on (0-10 scale)\n\nExclusion Criteria:\n\n* Cognitive impairment that would preclude response to study assessments or require the use of Legally Authorized Representatives\n* Unwilling to accept random assignment\n* Concurrently enroll onto ongoing competing trials of integrative medicine interventions with symptom\u002Ftoxicity as primary outcome. Note, however, patient will be allowed to enroll on other therapeutic protocols",{"count":307,"type":21},324,[63],"The overarching long-term goal of the Integrative Medicine for Patient-reported Outcomes Values and Experience (IMPROVE) research program is to evaluate whether integrating a virtual mind-body programming, Integrative Medicine at Home (IM@Home), will improve patient perceived values, outcomes, and experiences as they undergo systemic cancer treatment such as chemotherapy, immunotherapy, radiotherapy, targeted agents, cytoreductive surgery.",[32,311,312,313,28,314,27,229],"Head and Neck Tumor","Thoracic Tumor","Thoracic Cancer","Gynecologic Tumor",[32,316,317,318,319,320,321,322],"head and neck tumor","thoracic tumors","gynecological tumors","melanoma","21-369","Memorial Sloan Kettering Cancer Center","ovarian cancer",{"date":263,"type":43},{"date":325,"type":43},"2021-09-20",{"date":327,"type":21},"2026-09-20",{"name":321,"class":50},7,{"id":331,"slug":332,"hasResults":12,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":4,"eligibilityCriteria":336,"healthyVolunteers":337,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":338,"targetDuration":4,"studyType":61,"phases":340,"briefSummary":341,"conditions":342,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":350,"locationsCount":150},"100482495","chatbot-to-maximize-hereditary-cancer-genetic-risk-assessment-100482495","NCT05562778","Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment","Evaluation of a Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment in an Underserved Gynecology Population","Inclusion Criteria:\n\n* 8 years of age or older.\n* Scheduled for a New Patient appointment in the gynecology clinic. Speaks and reads in English.\n* Access to a telephone with texting capacity.\n* Has not had prior genetic testing for hereditary cancer syndromes.\n\nExclusion Criteria:\n\n* Under 18 years of age\n* Has had previous genetic testing for hereditary cancer syndromes\n* Does not read\u002Fspeak in English\n* Does not have access to a phone with texting capabilities",true,{"count":339,"type":21},150,[63],"In this study, the investigators aim to compare a mobile health platform, known as a 'chatbot,' that leverages artificial intelligence and natural language processing to scale communication, to 'usual care' that patients would receive. This comparison will enable the investigators to determine if the chatbot system can improve rates of recommendation for genetic testing among patients at elevated risk of harboring a familial cancer syndrome in an all-Medicaid gynecology clinic. Furthermore, the investigators aim to evaluate facilitators of inequity in regard to patient access to and utilization of genetic testing services.",[28,343],"Hereditary Cancer Syndrome","2026-06-18",{"date":346,"type":43},"2026-06-23",{"date":348,"type":43},"2023-01-15",{"date":246,"type":21},{"name":351,"class":50},"Weill Medical College of Cornell University",{"id":353,"slug":354,"hasResults":12,"nctId":355,"briefTitle":356,"officialTitle":357,"acronym":358,"eligibilityCriteria":359,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":360,"targetDuration":4,"studyType":61,"phases":362,"briefSummary":363,"conditions":364,"keywords":366,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":374,"locationsCount":376},"100588091","bolster-learning-new-skills-to-thrive-100588091","NCT06936878","BOLSTER: Learning New Skills to Thrive","BOLSTER: Strengthening Patient and Caregiver Supports in Advanced Gynecologic and Gastrointestinal Cancers","BOLSTER","Participant Inclusion Criteria:\n\n* Age ≥18 years\n* Currently hospitalized with skilled care need or have acquired a new skilled care need as an outpatient\n* Diagnosed with advanced gastrointestinal cancer (esophageal, gastric, pancreatic, hepatobiliary, colorectal, unknown GI primary, anal) or advanced gynecologic cancer (ovarian, endometrial, cervical, vaginal, vulvar)\n* Has a complex care need (e.g., ostomy, ileostomy, urostomy, nephrostomy, biliary drain, venting gastric tube, feeding tube, intraabdominal or pleural catheter, wound VAC)\n* Plans to receive ongoing cancer treatment\n* Has a family caregiver or friend (hereafter designated family caregiver) willing to participate\n* Able to speak and read English or Spanish (self-report)\n* Are willing to be audio-recorded\n* Have the cognitive\u002Fphysical ability to participate in a 60-minute interview\n\nFamily or Caregiver Inclusion Criteria:\n\n* Age ≥ 18 years\n* Identified by a patient (as defined above) as a family or friend who is involved in their care.\n* Willing to participate in study visits\n* Willing to be audio recorded\n\nParticipant Exclusion Criteria:\n\n* Has cognitive impairments (as determined by the patient's oncologist)\n* Planning to enroll in hospice\n* Unable to complete baseline survey\n* Adults unable to consent\n* Individuals who are not yet adults (infants, children, teenagers)\n* Prisoners\n\nFamily or Caregiver Exclusion Criteria:\n\n* Unable to complete baseline survey\n* Adults unable to consent\n* Individuals who are not yet adults (infants, children, teenagers)\n* Prisoners",{"count":361,"type":21},600,[63],"This research study is evaluating a new program called Building Out Lifelines for Safety, Trust, Empowerment, and Renewal or (BOLSTER), which was designed to support participants with a gynecological or gastrointestinal cancer and new and complex care needs.",[31,28,365],"Advanced Cancer",[31,28,365,367,368],"Advanced Gastrointestinal Cancer","Advanced Gynecologic Cancer","2026-06-16",{"date":344,"type":43},{"date":372,"type":43},"2025-05-12",{"date":294,"type":21},{"name":375,"class":50},"Dana-Farber Cancer Institute",2,{"id":378,"slug":379,"hasResults":12,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":4,"eligibilityCriteria":383,"healthyVolunteers":12,"sex":106,"minAge":18,"maxAge":4,"enrollmentInfo":384,"targetDuration":4,"studyType":61,"phases":386,"briefSummary":387,"conditions":388,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":391,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":150},"100526800","cryocompression-to-reduce-chemotherapy-induced-peripheral-neuropathy-in-gynecologic-cancer---cohort-2-100526800","NCT06139458","Cryocompression to Reduce Chemotherapy-induced Peripheral Neuropathy in Gynecologic Cancer - COHORT 2","Use of Cryocompression to Reduce Chemotherapy-induced Peripheral Neuropathy in Gynecologic Cancer: a Randomized Controlled Trial - COHORT 2","Inclusion Criteria:\n\n* Gynecologic cancer diagnosis (ovarian, cervical, endometrial cancer; adenocarcinomas of likely primary gynecologic origin based on cytology or FNA in conjunction with radiologic impression will be eligible)\n* Plan to receive at least 6 cycles of paclitaxel administered every 3 weeks at the Duke Cancer Center or Macon Pond or at the Carilion Clinic in Roanoke, VA. Patients receiving neoadjuvant chemotherapy with a plan for interval debulking will be eligible.\n* ECOG (Eastern Cooperative Oncology Group) performance status of 0-1\n\nExclusion Criteria:\n\n* Treated with prior neurotoxic chemotherapeutic agents\n* Baseline diagnosis of peripheral neuropathy such as diabetic neuropathy, or conditions including but not limited to fibromyalgia, cryoglobulinemia and Raynaud's disease.",{"count":385,"type":21},190,[63],"The investigators aim to determine the effect of cryotherapy wraps plus compression therapy (henceforth referred to as cryocompression) versus cryotherapy wraps alone on the incidence and degree of chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer using a noninferiority design. The investigators also aim to determine the effect of cryocompression versus cryotherapy on patient tolerability and patient and staff satisfaction.",[28,389],"Chemotherapy-induced Peripheral Neuropathy","2026-06-01",{"date":392,"type":43},"2026-06-02",{"date":394,"type":43},"2024-01-18",{"date":396,"type":21},"2027-05-31",{"name":398,"class":50},"Duke University",{"id":400,"slug":401,"hasResults":12,"nctId":402,"briefTitle":403,"officialTitle":404,"acronym":405,"eligibilityCriteria":406,"healthyVolunteers":12,"sex":106,"minAge":18,"maxAge":4,"enrollmentInfo":407,"targetDuration":4,"studyType":61,"phases":409,"briefSummary":410,"conditions":411,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":415,"completionDateStruct":417,"leadSponsor":419,"locationsCount":51},"100602176","transcranial-magnetic-stimulation-for-chemotherapy-induced-peripheral-neuropathy-in-breast-and-gynecologic-cancer-survivors-100602176","NCT07120100","Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy in Breast and Gynecologic Cancer Survivors","Repetitive Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Breast and Gynecologic Cancer Survivors: A Pilot Study","rTMS for CIPN","Inclusion Criteria:\n\n* Female subjects aged ≥ 18 years.\n* Histologically confirmed breast or gynecologic cancer.\n* Developed neuropathic pain with the initiation of or within one month after completion of treatment with anti-neoplastic agents from the following class:\n\n  * Platinum-based drugs\n  * Taxanes\n  * Vinca alkaloids\n* Pain score 4 or more on the Pain Numeric Rating Scale (PNRS).\n* Score 3 or more on the Douleur Neuropathique 4 (DN-4) questionnaire.\n* Subjects must have failed at least one standard-of-care neuropathic medication.\n\n  \\--- Note: Failure is defined as discontinuation of the standard-of-care neuropathic pain medication due to intolerable side effects or lack of analgesic benefit after continuing the medication for at least 6 weeks.\n* Subjects who are currently on neuropathic medication must have been on a stable dose for at least 6 weeks prior to enrollment.\n\n  \\-- Note: Additional washout periods for other pain medications may be needed and will be determined by the Investigator.\n* For female subjects: Negative pregnancy test or evidence of post-menopausal status. The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause or having undergone surgical sterilization (bilateral oophorectomy or hysterectomy). The following age-specific requirements apply:\n\n  * Women \\\u003C 50 years of age:\n\n    * Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and\n    * Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution; or\n    * Underwent surgical sterilization (bilateral oophorectomy or hysterectomy).\n  * Women ≥ 50 years of age:\n\n    * Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or\n    * Had radiation-induced menopause with last menses \\>1 year ago; or\n    * Had chemotherapy-induced menopause with last menses \\>1 year ago; or\n    * Underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).\n* Subjects of childbearing potential must agree to use a highly effective method of contraception as described in Section 5.4.1.\n* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.\n\nExclusion Criteria:\n\n* Evidence of recurrent breast or gynecologic cancer at the time of enrollment.\n* Current or planned treatment with chemotherapy.\n\n  --Note: Other anti-cancer treatments (e.g. hormone therapy and targeted therapies) are allowed at the Investigator's discretion.\n* History of seizure, epilepsy, or other conditions that would, in the opinion of the investigator, negatively impact the patient's safety or ability to participate in the study.\n* Presence of neuropathic pain unrelated to systemic cancer therapy, including but not limited to: painful diabetic neuropathy, HIV-induced neuropathy, neuropathic pain from radiation therapy and underlying cancer\u002Fother medical conditions.\n* Presence of implantable devices including spinal cord stimulators, dorsal root ganglion stimulators, deep brain stimulators, cochlear implants, intrathecal pain pumps, and intracranial metallic objects which are incompatible with rTMS administration in the opinion of the treating investigator.\n* Subjects on medications that, in the opinion of the investigator, significantly lower seizure threshold will be excluded.\n* Any condition that would, in the Investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures.\n* History of recent suicide attempt or active suicidal ideation that, in the opinion of the investigator, presents an increased risk for study participation\n* Medical, psychiatric, cognitive, or other conditions that may compromise the subject's ability to understand the subject information, give informed consent, comply with the study protocol or complete the study.\n* Enrollment in another study that, in the opinion of the investigator, would negatively impact study participation or cause undue burden for the subject.",{"count":408,"type":21},19,[63],"The goal of this study is to evaluate the change in pain scores among patients with chemotherapy-induced peripheral neuropathy after receiving treatment with repetitive transcranial magnetic stimulation (rTMS).",[412,28],"Breast Cancer Female","2026-05-29",{"date":392,"type":43},{"date":416,"type":43},"2025-08-27",{"date":418,"type":21},"2028-09-15",{"name":97,"class":50},{"id":421,"slug":422,"hasResults":12,"nctId":423,"briefTitle":424,"officialTitle":424,"acronym":425,"eligibilityCriteria":426,"healthyVolunteers":12,"sex":106,"minAge":18,"maxAge":4,"enrollmentInfo":427,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":428,"conditions":429,"keywords":430,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":51},"100623549","pilot-observational-study-of-an-integrative-cure-stay-program-100623549","NCT07398079","Pilot Observational Study of an Integrative Cure Stay Program","Via Shalva","Inclusion Criteria:\n\n* Breast and gynecological cancer (including but not limited to ovarian, endometrial, cervical, vulvar and vaginal cancer) survivors, including recurrent disease\n* Completed primary treatment (operation +\u002F- radiation +\u002F- chemotherapy)\n* Age ≥ 18 years\n* Ongoing or planned maintenance treatment scheduled for \\> 3 months during study period is allowed (e.g. antihormonal therapy, Anti-Her2-antibodies, CDK4\u002F6-inhibitors, Anti-VEGF-inhibitor, PARP-inhibitor, immune-checkpoint inhibitors etc.)\n* Signed informed consent for participation of the trials\n* Presence of a stoma is allowed\n* Prior cancer is allowed\n* Prior treatment - including chemotherapy - for a prior malignant tumor (including breast or gynecological cancer) is allowed\n* Concomitant participation in an experimental therapeutic drug trial is allowed\n* Use of other complementary methods (including mistletoe) is allowed\n* Pregnancy is allowed.\n\nExclusion Criteria:\n\n* Language or cognitive deficits (including impaired consciousness) that are incompatible with the participation in the study\n* Severe physical or psychiatric comorbidity that prevents a patient from participating in the study\n* Patients incapable of giving consent",{"count":60,"type":21},"This pilot observational study evaluates the feasibility and acceptability of conducting a prospective study alongside the individualized integrative oncology cure stay program \"Via Shalva\" for breast and gynecological cancer survivors. The study further explores preliminary changes in patient-reported outcomes, physiological measures, and biological markers before and after the retreat and compared with a matched control group.",[25,28],[431,432,433],"Complementary Therapies","Integrative Medicine","Feasibility Studies","2026-05-19",{"date":436,"type":43},"2026-05-22",{"date":438,"type":43},"2025-10-06",{"date":440,"type":21},"2027-06",{"name":442,"class":50},"University Hospital, Basel, Switzerland",{"id":444,"slug":445,"hasResults":12,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":4,"eligibilityCriteria":449,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":450,"targetDuration":4,"studyType":61,"phases":452,"briefSummary":453,"conditions":454,"keywords":4,"overallStatus":205,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":456,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":462,"locationsCount":51},"100638028","ocra-distress--unmet-needs-100638028","NCT07591623","OCRA Distress & Unmet Needs","Identifying And Addressing Distress And Unmet Needs Of Gynecologic Cancer Caregivers","Inclusion Criteria:\n\nThis study will include participants from two categories:\n\nPatients:\n\n1. Must be at least 18 years old\n2. Must read and speak English or Spanish\n3. Participants must have access to the internet via a smartphone, tablet, or computer (public or private), or have reliable access to a telephone to communicate with the study coordinator.\n4. Patient presenting for initial or recurrence chemotherapy treatment for management of a gynecologic malignancy (cancer of the ovary, uterus, cervix, vulva, vagina, peritoneum, or fallopian tube)\n5. No physical, psychological, or cognitive impairments that would preclude participation and ability to understand the consent statement\n\nCaregivers:\n\n1. Must be at least 18 years old\n2. Must read and speak English or Spanish\n3. Participants must have access to the internet via a smartphone, tablet, or computer (public or private), or have reliable access to a telephone to communicate with the study coordinator.\n4. Must be an identified caregiver of an enrolled patient\n5. No physical, psychological, or cognitive impairments that would preclude participation and ability to understand the consent statement\n\nThe study will include patients with no caregiver, and only one caregiver may enroll per patient.\n\nExclusion Criteria:\n\nPatients:\n\n1\\. Unwilling or unable to proceed beyond the consent statement step Caregivers\n\n1\\. Unwilling or unable to proceed beyond the consent statement step",{"count":451,"type":21},250,[63],"This study is a prospective longitudinal cohort study with an embedded intervention. It follows participants with gynecologic malignancies and their informal caregivers over a 6-month period to assess caregiver distress, NMDOH, and patient outcomes.",[28],"2026-05-13",{"date":457,"type":43},"2026-05-18",{"date":459,"type":21},"2026-10-01",{"date":461,"type":21},"2029-03-31",{"name":463,"class":50},"M.D. Anderson Cancer Center",{"id":465,"slug":466,"hasResults":12,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":4,"eligibilityCriteria":470,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":471,"targetDuration":4,"studyType":61,"phases":473,"briefSummary":475,"conditions":476,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":488,"startDateStruct":489,"completionDateStruct":491,"leadSponsor":493,"locationsCount":51},"100567833","phase-1-brodalumab-in-the-treatment-of-immune-related-adverse-events-100567833","NCT06673329","Brodalumab in the Treatment of Immune-Related Adverse Events","Safety and Efficacy of Brodalumab in the Treatment of Immune-Related Adverse Events: A Pilot Study","Inclusion Criteria:\n\n* Ability to provide written informed consent by subject or guardian\n* Individuals \\>18 years of age\n* Diagnosis of an irAE clinically suspected to be IL-17 mediated\n* Intent-to-treat or prior treatment with systemic steroids for irAE management\n* Histology-proven primary advanced or metastatic solid organ malignancy treated with immunotherapy. Patients being treated with curative intent are not eligible to enroll.\n* Subject has a negative test for tuberculosis during screening defined as either: negative purified protein derivative (PPD) (\\\u003C 5 mm of induration at 48 to 72 hours after test is placed) OR negative QuantiFERON test. Tuberculosis testing must be performed within 30 days prior to trial initiation.\n* Subjects with a positive PPD and a history of Bacillus Calmette-Guérin vaccination are allowed with a negative QuantiFERON test.\n* Subjects with a positive PPD test (without a history of Bacillus Calmette-Guérin vaccination) or subjects with a positive or indeterminate QuantiFERON test are allowed if they have all of the following: no symptoms of tuberculosis (defined as fever, shortness of breath, cough or night sweats), documented history of a completed course of adequate prophylaxis (per local standard of care), no known exposure to a case of active tuberculosis after most recent prophylaxis, no evidence of active tuberculosis on chest radiograph within 3 months prior to the first dose of brodalumab.\n\nExclusion Criteria:\n\n* Estimated creatinine clearance \\\u003C 40 mg\u002Fmin\n* Active suicidal ideation or severe depression (as defined by the Diagnostic and Statistical Manual of Mental Disorders Version IV criteria (DSM-IV)) at the time of enrollment or a PHQ-9 score \\> 20\n* History of prior suicide attempts\n* PHQ-9 score greater \\>5 and \\\u003C 20 without an established mental health provider who verifies stability in their depression\n* Current or prior drug or alcohol abuse within the past 6 months (as defined by the DSM IV)\n* In the opinion of the investigator, the patient requires additional immunosuppressive treatment (other than corticosteroids and brodalumab)\n* Known hypersensitivity or contraindication to brodalumab, corticosteroids or any components of brodalumab\n* Prior treatment with brodalumab\n* Pregnancy, breastfeeding, or use of a nonreliable method of contraception\n\n  * For patients assigned female at birth: lack of willingness to use highly effective methods of birth control during treatment and for at least 4 weeks after the last dose of brodalumab (except if surgically sterile or at least 2 years postmenopausal, with postmenopausal status confirmed by Follicle-Stimulating Hormone (FSH) in the postmenopausal range).\n  * Highly effective methods of birth control include: use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. Oral contraceptive pills must be supplemented by a barrier method.\n  * Patients planning to become pregnant while enrolled in the study and within 4 weeks after the last dose of brodalumab will not be permitted to enroll\n* Chronic or current severe infection requiring IV therapy\n* Evidence of active hepatitis B, C, or tuberculosis.\n* History of latent tuberculosis infection which is incompletely treated based upon local standard of care or which was never treated\n* History of or active Crohn's disease.\n* Myocardial infarction, unstable angina pectoris or stroke within the past 12 months prior to the first investigational product dose\n* Any concurrent medical condition or electrocardiogram (ECG) abnormality that, in the opinion of the investigator, could cause this study to be detrimental to the subject.\n* Any medical condition or treatment for a condition that, in the opinion of the investigator, might interfere with participation in the study or affect the reliability of clinician assessment or patient self-report\n* Other known clinically significant active medical conditions, such as:\n\n  * Severe cardiovascular disease, including advanced heart failure (American Heart Association Stage D)\n  * Aspartate aminotransferase (AST) and or alanine aminotransferase (ALT) greater than 2 times the upper limit of normal or greater than 3 times the upper limit of normal in patients with liver metastases measured on at least two separate occasions\n  * Direct bilirubin greater than or equal to 1.5 mg\u002FdL in patients with or without liver metastases\n  * Bone marrow insufficiency unrelated to the irAE (according to investigator judgment) with White Blood Cell (WBC) \\\u003C2000\u002Fmm3, absolute neutrophil count \\\u003C1500\u002F mm3, thrombocytopenia (platelet count) \\\u003C50,000\u002Fmm3, hemoglobin \\\u003C 8.0 g\u002FdL\n* Plan to proceed with further curative intent treatment for cancer at the time of enrollment despite the presence of irAE\n* Participation in another therapeutic clinical trial and receipt of investigational drugs within 4 weeks before the screening visit\n* Previous diagnosis of an autoimmune disease or administration of immunosuppressants in a time frame that would impede interpretation of brodalumab administration\n* Planned use of immunosuppressive agents other than steroids (including infliximab, vedolizumab, tocilizumab etc.) or administration of such agents within 28 days of trial initiation\n* Administration of live-virus vaccines within 4 weeks before the first dose of brodalumab",{"count":472,"type":21},11,[474],"PHASE1","The purpose of this study is to test the safety and effectiveness of using brodalumab in patients who develop side effects from cancer immune therapy. Immune-related side effects are due to activation of the immune system in patients who previously received immunotherapy and the goal of this study is to help better control these side effects. Brodalumab is often used to treat patients with autoimmune diseases (diseases where the immune system is activated against normal organs) and safe doses and treatment schedules have been determined in these patients. Immune-related side effects appear to closely mirror these autoimmune conditions. Brodalumab has not been approved by the United States Food and Drug Administration (FDA) for use in immunotherapy side effects but it has been approved for treatment of autoimmune conditions.",[25,477,240,26,478,28,479,480,481,482,483,32,484,230,170,168,485,486],"Esophageal Cancer","Thyroid Cancer","Pancreatic Cancer","Stomach Cancer","Brain Tumor","Colon Cancer","Rectal Cancer","Oral Cancer","Testicular Cancer","Solid Tumor","2026-05-11",{"date":455,"type":43},{"date":490,"type":43},"2025-03-11",{"date":492,"type":21},"2027-11",{"name":494,"class":50},"Brian Henick, MD",{"id":496,"slug":497,"hasResults":12,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":501,"eligibilityCriteria":502,"healthyVolunteers":12,"sex":106,"minAge":18,"maxAge":4,"enrollmentInfo":503,"targetDuration":505,"studyType":22,"phases":4,"briefSummary":506,"conditions":507,"keywords":509,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":51},"100635915","the-surveillance-epidemiology-and-end-results-database-program-on-endometrial-cancer-in-the-italian-population-100635915","NCT07558889","The Surveillance, Epidemiology, and End Results Database Program on Endometrial Cancer in the Italian Population","The ENDOCancer-DATA: the Surveillance, Epidemiology, and End Results Database Program on Endometrial Cancer in the Italian Population","ENDOCancerDATA","Inclusion Criteria:\n\n* diagnosis of endometrial cancer (stage I-IV, G1-3, and special histotypes)\n* age \\> 18 years\n* American Society of Anesthesiologists classification (ASA score) 1-3\n* patients undergoing staging, cytoreduction or diagnostic surgery with acquisition of histological examination on which IHC and\u002For NGS studies have been performed for the molecular profile of the carcinoma\n* Signed informed consent\n\nExclusion Criteria:\n\n* patients with missing information\n* patients not treated in the participating centers for which only partial and fragmented information will be available\n* molecular profile not known and\\\\or not recoverable and retrospectively analysable",{"count":504,"type":21},10000,"10 Years","The aim of this study is to lay the bases for an ambitious project that reports and records all the epidemiological-clinical information of the cases of endometrial carcinoma diagnosed and treated in the reference oncology centers involved on the national territory, to create a process of analysis of the data",[508,28],"Endometrium Cancer",[510,511,512,513,514,515],"Molecular classification","Endometrial cancer treatment","Endometrial cancer epidemiology","Endometrial cancer surgical procedures","Minimally invasive surgery","Gynecologic Oncology","2026-04-27",{"date":518,"type":43},"2026-04-30",{"date":520,"type":43},"2024-04-01",{"date":522,"type":21},"2034-01-01",{"name":214,"class":50},{"id":525,"slug":526,"hasResults":12,"nctId":527,"briefTitle":528,"officialTitle":529,"acronym":530,"eligibilityCriteria":531,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":107,"enrollmentInfo":532,"targetDuration":4,"studyType":61,"phases":534,"briefSummary":536,"conditions":537,"keywords":541,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":543,"lastUpdatePostDateStruct":544,"startDateStruct":545,"completionDateStruct":547,"leadSponsor":549,"locationsCount":51},"100495050","phase-4-fluid-challenge-and-plasma-volume-during-surgery-100495050","NCT05726136","Fluid Challenge and Plasma Volume, During Surgery","Comparison of Albumin and Ringer's Solution for Optimization of the Plasma Volume and Hemodynamics During Laparoscopic Surgery.","FC-VE","Inclusion Criteria:\n\n* Written consent to participate in the study\n* For women: relevant contraceptive, menopausal or a negative pregnancy test.\n* ASA category I to III\n* Laparoscopic abdominal surgery, with a duration of at least 90 minutes.\n* 18 to 85 years\n\nExclusion Criteria:\n\n* Patients with known cardiac failure\n* \\\u003C18 or \\>85 years\n* known allergy to albumin\n* extracellular hyperhydration or hypervolemia\n* kidney failure\n* pregnancy or planned pregnancy",{"count":533,"type":21},60,[535],"PHASE4","A short bolus infusion of fluid, called \"fluid challenge\" is commonly recommended for fluid treatment during longer surgery. However a prolonged increase of the blood volume is a prerequisite to recommend the technique. The purpose with the study is to examine the plasma expanding effect of three different fluid challenge strategies (acetated Ringers 4 ml\u002Fkg body weight, albumin 5% 4 ml\u002Fkg body weight or albumin 20% 1 ml\u002Fkg body weight), using hemoglobin as a dilution indicator.",[167,538,28,539,540],"Urologic Cancer","Colorectal Disorders","Benign Neoplasm",[542],"laparoscopic surgery, fluid therapy, plasma volume","2026-04-24",{"date":518,"type":43},{"date":546,"type":43},"2023-10-23",{"date":548,"type":21},"2026-10-31",{"name":550,"class":50},"Joachim Zdolsek",{"id":552,"slug":553,"hasResults":12,"nctId":554,"briefTitle":555,"officialTitle":556,"acronym":4,"eligibilityCriteria":557,"healthyVolunteers":12,"sex":106,"minAge":18,"maxAge":4,"enrollmentInfo":558,"targetDuration":4,"studyType":61,"phases":560,"briefSummary":561,"conditions":562,"keywords":565,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":566,"lastUpdatePostDateStruct":567,"startDateStruct":569,"completionDateStruct":571,"leadSponsor":573,"locationsCount":51},"100482273","phase-1-cabozantinib-and-dostarlimab-in-recurrent-gynecologic-carcinosarcoma-100482273","NCT05559879","Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma","A Phase Ib\u002FII Single Arm Study of Cabozantinib Plus Dostarlimab in Women With Recurrent Gynecologic Carcinosarcoma","Inclusion Criteria:\n\n1. Histologically confirmed diagnosis of carcinosarcoma (independent of organ of gynecologic origin)\n2. Received at least one prior chemotherapy regimen for their cancer\n3. Must have measurable or evaluable lesion defined by iRECIST\n4. Recovery to baseline or ≤ Grade 1 CTCAE v5.0 from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and\u002For stable on supportive therapy\n5. ECOG Performance Status of 0-2\n6. Age ≥ 18 years\n7. Adequate organ and marrow function, based upon meeting all of the following laboratory criteria within 14 days before first dose of study treatment:\n\n   1. Absolute neutrophil count (ANC) ≥ 1500\u002Fmm3 (≥ 1.5 GI\u002FL) without granulocyte colony-stimulating factor support.\n   2. White blood cell count ≥ 2500\u002Fmm3 (≥ 2.5 GI\u002FL).\n   3. Platelets ≥ 100,000\u002Fmm3 (≥ 100 GI\u002FL) without transfusion.\n   4. Hemoglobin ≥ 9 g\u002FdL (≥ 90 g\u002FL).\n   5. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) ≤ 3 x upper limit of normal (ULN). ALP ≤ 5 x ULN with documented bone metastases.\n   6. Total bilirubin ≤ 1.5 x ULN (for patients with Gilbert's disease ≤ 3 x ULN).\n   7. Serum albumin ≥ 2.8 g\u002Fdl.\n   8. Serum creatinine ≤ 2.0 x ULN or calculated creatinine clearance ≥ 30 mL\u002Fmin (≥ 0.5 mL\u002Fsec) using the Cockcroft-Gault equation:\n\n   \\[(140 - age) x weight (kg)\u002F(serum creatinine \\[mg\u002FdL\\] × 72)\\] × 0.85 i. Urine protein\u002Fcreatinine ratio (UPCR) ≤ 1 mg\u002Fmg (≤ 113.2 mg\u002Fmmol).\n8. Capable of understanding and complying with the protocol requirements and must have signed the informed consent document.\n9. Women of childbearing potential (WOCBP) ie. sexually active fertile patients and their partners must agree to use medically accepted methods of contraception (e.g., barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for 5 months after the last dose of study treatment.\n10. Females should not breastfeed while receiving treatment on trial.\n11. Female patients of childbearing potential must not be pregnant at screening. Females of childbearing potential are defined as premenopausal females capable of becoming pregnant (i.e., females who have had any evidence of menses in the past 12 months, with the exception of those who had a prior hysterectomy). However, women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, low body weight, ovarian suppression, or other reasons.\n\nExclusion Criteria:\n\n1. Prior treatment with cabozantinib.\n2. Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks or 5 half-lives (whichever is longer) before first dose of study treatment.\n3. Receipt of any type of cytotoxic, biologic, or other systemic anticancer therapy (including investigational) within 4 weeks before first dose of study treatment.\n4. Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks before first dose of study treatment. Systemic treatment with radionuclides within 6 weeks before the first dose of study treatment. Patients with clinically relevant ongoing complications from prior radiation therapy are not eligible.\n5. Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and\u002For surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment. Eligible patients must be neurologically asymptomatic and without corticosteroid treatment at the time of first dose of study treatment.\n6. Concomitant anticoagulation with coumarin agents (e.g., warfarin), direct thrombin inhibitors (e.g., dabigatran), direct factor Xa inhibitor betrixabin, or platelet inhibitors (e.g., clopidogrel). Allowed anticoagulants are the following:\n\n   1. Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines) and low-dose low molecular weight heparins (LMWH).\n   2. Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban in subjects without known brain metastases who are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor.\n7. The patient has prothrombin time (PT)\u002FINR or partial thromboplastin time (PTT) test ≥ 1.3 X the laboratory ULN within 7 days before the first dose of study treatment.\n8. The patient has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:\n\n   a. Cardiovascular disorders: i. Congestive heart failure New York Heart Association Class 3 or 4, unstable angina pectoris, serious cardiac arrhythmias.\n\n   ii. Uncontrolled hypertension defined as sustained blood pressure (BP) \\> 140 mm Hg systolic or \\> 90 mm Hg diastolic despite optimal antihypertensive treatment.\n\n   iii. Stroke (including transient ischemic attack \\[TIA\\]), myocardial infarction (MI), or other ischemic event, or thromboembolic event (e.g., deep venous thrombosis, pulmonary embolism) within 6 months before first dose.\n\n   b. Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation: i. The patient has evidence of tumor invading the GI tract, active peptic ulcer disease, inflammatory bowel disease (e.g., Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis, acute obstruction of the pancreatic duct or common bile duct, or gastric outlet obstruction.\n\n   ii. Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal abscess within 6 months before first dose.\n\n   Note: Complete healing of an intra-abdominal abscess must be confirmed before first dose.\n\n   c. Clinically significant hematuria, hematemesis, or hemoptysis of \\> 0.5 teaspoon (2.5 ml) of red blood, or other history of significant bleeding (e.g., pulmonary hemorrhage) within 12 weeks before first dose.\n\n   d. Cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease manifestation.\n\n   e. Lesions invading or encasing any major blood vessels. f. Other clinically significant disorders that would preclude safe study participation.\n\n   i. Serious non-healing wound\u002Fulcer\u002Fbone fracture ii. Uncompensated\u002Fsymptomatic hypothyroidism (i.e. inadequately treated hypothyroidism) iii. Moderate to severe hepatic impairment (Child-Pugh B or C)\n9. Major surgery (e.g., laparoscopic nephrectomy, GI surgery, removal or biopsy of brain metastasis) within 2 weeks before first dose of study treatment. Minor surgeries within 10 days before first dose of study treatment. Subjects must have complete wound healing from major surgery or minor surgery before first dose of study treatment. Subjects with clinically relevant ongoing complications from prior surgery are not eligible.\n10. Corrected QT interval calculated by the Fridericia formula (QTcF) \\> 500 ms per electrocardiogram (ECG) within 28 days before first dose of study treatment \\[add reference for Fridericia formula\\].\n\n    Note: If a single ECG shows a QTcF with an absolute value \\> 500 ms, two additional ECGs at intervals of approximately 3 min must be performed within 30 min after the initial ECG, and the average of these three consecutive results for QTcF will be used to determine eligibility.\n11. Inability to swallow tablets.\n12. Previously identified allergy or hypersensitivity to components of the study treatment formulations.\n13. Diagnosis of another malignancy within 2 years before first dose of study treatment, except for superficial skin cancers, or localized, low-grade tumors deemed cured and not treated with systemic therapy.\n14. Patients with concurrent cytotoxic chemotherapy or radiation therapy are excluded.\n15. Patients with a serious chronic or acute illness, such as cardiac disease (NYHA class III or IV), hepatic disease, or other illness considered by the Principal Investigator as unwarranted high risk for investigational drug treatment.\n16. Patients with a medical or psychological impediment to probable compliance with the protocol should be excluded.\n17. Presence of a known active acute or chronic infection including: a urinary tract infection, HIV or viral hepatitis; however, it is acceptable to treat an acute infection and then re-screen or re-evaluate eligibility.\n18. Administration of a live, attenuated vaccine within 30 days prior to first dose of study treatment\n19. Other clinically significant disorders:\n\n    1. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.\n    2. Active, known, or suspected autoimmune disease (exceptions: type 1 diabetes mellitus, hypothyroidism, skin disorders, conditions not expected to recur in the absence of an external trigger)\n    3. Malabsorption syndrome\n    4. Requirement for hemodialysis or peritoneal dialysis\n    5. History of solid organ or allogenic stem cell transplant",{"count":559,"type":21},37,[474,85],"Immunotherapy has gained a significant amount of attention recently, but its efficacy as a single agent in gynecological cancers has been disappointing. Pre-clinical evidence supports the combination of using Vascular Endothelial Growth Factors (VEGF) inhibitors with immunotherapy. VEGF inhibitors suppress the activation of tumor-associated macrophages (TAMs) and VEGF has been shown to affect the functional maturation of dendritic cells; therefore, VEGF inhibitors could improve the function of antigen presentation. In this study, Cabozantinib (VEGF inhibitor) and Dostarlimab (immunotherapeutic drug) will be admnistered as a combination to patients with recurrent gynecologic carcinosarcoma.",[28,563,564,202],"Carcinoma","Uterine Cancer",[28,563,564,202],"2026-04-10",{"date":568,"type":43},"2026-04-15",{"date":570,"type":43},"2023-08-20",{"date":572,"type":21},"2027-04",{"name":574,"class":50},"University of Alabama at Birmingham",{"id":576,"slug":577,"hasResults":12,"nctId":578,"briefTitle":579,"officialTitle":579,"acronym":580,"eligibilityCriteria":581,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":582,"targetDuration":4,"studyType":61,"phases":584,"briefSummary":585,"conditions":586,"keywords":589,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":592,"lastUpdatePostDateStruct":593,"startDateStruct":595,"completionDateStruct":597,"leadSponsor":599,"locationsCount":51},"100463322","prospective-evaluation-of-pencil-beam-scanning-proton-therapy-for-previously-irradiated-tumors-100463322","NCT05313191","Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors","ReRT","Inclusion Criteria:\n\n* Age 18 years\n* Patient provides study specific informed consent prior to study entry.\n* Documented history and physical exam within 90 days prior to registration.\n* ECOG PS 0, 1, or 2 within 90 days prior to registration\n\nExclusion Criteria:\n\n* Non malignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow up.\n* Prior invasive non study malignancy unless disease free for ≥ 3 years\n\n  * Non melanoma skin cancer, low risk prostate cancer, well differentiated thyroid cancers, in situ carcinomas of the oral cavity, cervix, and other organs, and tumors that are not thought to impact the life expectancy of the patient are permissible.\n* History of active connective tissue disorder (i.e., systemic lupus erythematosus, scleroderma), dermatomyositis, xeroderma pigmentosum",{"count":583,"type":21},1800,[63],"The goal of this clinical research trial is to study the use of differing investigational doses and scheduling for Proton Therapy for tumors previously treated with radiation therapy. Generally, when patients are first treated for cancer with radiation therapy, they are treated with traditional photon (or x-ray) radiation therapy, which uses high-energy waves to kill tumor cells. In some cases, the cancer either returns or a new tumor can present in a different part of the body. With the usual radiation treatment, the photon beams travel all the way through the body. As a result, healthy tissues in front of and behind the tumor are exposed to radiation. Physicians who treat these cases where the tumor has returned often use a much lower dose of radiation to prevent patients from experiencing serious and long-term side-effects. This dose is often not strong enough to destroy the cancerous tumor. Alternatively, they may also treat a smaller area than would be indicated for complete tumor eradication, again in an attempt to prevent serious and long-term toxicities, but at the cost of optimally treating the cancer. Proton therapy, however, may offer a chance to safely deliver a more effective dose and volume of radiation as it is more targeted and can spare healthy tissues surrounding the tumor.\n\nThe reason we are conducting this research study is to look at whether Proton therapy can be a better way to treat reoccurring tumors in patients who have previously received radiation therapy to the same area, compared to treatment approaches used to date.",[587,32,588,28,168,313,25],"CNS Cancer","GI Cancer",[590,117,591,140],"Reirradiation","Proton Therapy","2026-04-06",{"date":594,"type":43},"2026-04-13",{"date":596,"type":43},"2022-01-24",{"date":598,"type":21},"2028-01",{"name":600,"class":50},"The New York Proton Center",{"id":602,"slug":603,"hasResults":12,"nctId":604,"briefTitle":605,"officialTitle":606,"acronym":607,"eligibilityCriteria":608,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":609,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":611,"conditions":612,"keywords":615,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":620,"lastUpdatePostDateStruct":621,"startDateStruct":623,"completionDateStruct":625,"leadSponsor":627,"locationsCount":629},"100450172","avera-cancer-sequencing-and-analytics-protocol-asap-100450172","NCT05142033","Avera Cancer Sequencing and Analytics Protocol (ASAP)","Implementation of Comprehensive Molecular Profiling and Deep Clinical Annotation of Electronic Health Records in Participants Diagnosed With or at Risk of Developing Cancer (ASAP Study)","ASAP","Inclusion Criteria:\n\n* Must be at least 18 years of age\n* Must be undergoing a workup or being followed for a premalignant condition or have a diagnosis of cancer\n* Must voluntarily sign and understand the most current IRB-approved consent form prior to study participation\n\nExclusion Criteria:\n\n* Participants incapable of understanding the items listed in the consent form and process\n* Participants with a history of or known psychiatric illness deemed unable to consent or adhere to study requirements",{"count":610,"type":21},25000,"The purpose of this study is to characterize the breadth of molecular features present in participants receiving care within a large, integrated, community-based healthcare system. Through comprehensive genomic profiling, investigators aim to identify the underlying genomic drivers of premalignant and malignant conditions across a range of disease stages and cancer types.\n\nComprehensive molecular profiling will include somatic tumor testing (tissue and\u002For blood) using next-generation sequencing. Selected subsets of samples may undergo whole exome and\u002For whole transcriptome sequencing for research purposes. Pharmacogenomic testing will also be performed to better understand individual variability in medication response and to identify opportunities for optimizing treatment. In addition, participants may optionally provide microbiome samples.\n\nTo maximize the value of the genomic data, participants who consent to this protocol will have their electronic health records-both retrospective and prospective-abstracted, curated, annotated, and linked to the genomic data generated through study testing. Given the long-term value of these data, participants may also voluntarily consent to the storage of their biological samples in a biobank and to the use of their de-identified information for future research.\n\nData collected from this participant population will support efforts to advance the understanding of cancer biology, as well as the discovery and validation of biomarkers associated with clinical outcomes. Findings may also be shared through collaborative research initiatives to further promote advancements in cancer research.",[117,613,614,25,26,482,588,28,229,202,587,169],"Cancer Diagnosis","Early Detection of Cancer",[117,616,617,618,619],"Genomics","Genetics","Microbiome","Pharmacogenomics","2026-03-23",{"date":622,"type":43},"2026-03-27",{"date":624,"type":43},"2021-11-01",{"date":626,"type":21},"2026-12-31",{"name":628,"class":50},"Avera McKennan Hospital & University Health Center",6,{"id":631,"slug":632,"hasResults":12,"nctId":633,"briefTitle":634,"officialTitle":635,"acronym":636,"eligibilityCriteria":637,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":638,"targetDuration":640,"studyType":22,"phases":4,"briefSummary":641,"conditions":642,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":668,"lastUpdatePostDateStruct":669,"startDateStruct":671,"completionDateStruct":673,"leadSponsor":675,"locationsCount":677},"100368284","the-momentum-study-the-multiple-outcome-evaluation-of-radiation-therapy-using-the-mr-linac-study-100368284","NCT04075305","The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study","The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study","MOMENTUM","Inclusion Criteria:\n\n* Patient is to undergo or has completed imaging or treatment procedures on an MR-Linac;\n* Patient provides written, informed consent;\n* Patient is 18 years old or older.\n\nExclusion Criteria:\n\n* MRI exclusion criteria, including\n* MRI contraindications as per usual clinical care, such as (possible) pregnancy; claustrophobia and metal or electronic implants not compatible with MRI.",{"count":639,"type":21},8000,"2 Years","The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose to improve patients' survival, local, and regional tumor control and quality of life.",[643,25,168,28,481,238,314,644,645,646,647,648,483,649,650,26,651,652,477,653,654,655,656,657,479,658,659,32,660,311,661,662,663,664,230,665,666,667],"Oncology","Prostate Tumor","Prostate Neoplasm","Breast Tumor","Radiation Toxicity","Quality of Life","Rectal Tumor","Rectal Neoplasms","Lung Tumor","Lung Neoplasm","Esophagus Cancer","Esophageal Tumor","Esophageal Neoplasm","Esophagus Tumor","Esophagus Neoplasm","Pancreatic Tumor","Pancreatic Neoplasms","Head and Neck Neoplasms","Tumor","Neoplasms","Bladder Cancer","Bladder Neoplasm","Liver Neoplasms","Liver Metastases","Oligometastases","2026-03-03",{"date":670,"type":43},"2026-03-05",{"date":672,"type":43},"2019-02-01",{"date":674,"type":21},"2030-08-01",{"name":676,"class":50},"UMC Utrecht",18,{"id":679,"slug":680,"hasResults":12,"nctId":681,"briefTitle":682,"officialTitle":683,"acronym":4,"eligibilityCriteria":684,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":685,"targetDuration":4,"studyType":61,"phases":686,"briefSummary":687,"conditions":688,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":690,"lastUpdatePostDateStruct":691,"startDateStruct":692,"completionDateStruct":694,"leadSponsor":696,"locationsCount":51},"100627316","phase-2-riluzole-for-preventing-cognitive-dysfunction-in-ca-pts-receiving-chemo-refocus-pilot-trial-100627316","NCT07447050","Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial","RiluzolE FOr Preventing Cognitive DysfUnction in Cancer PatientS Receiving Chemotherapy (REFOCUS)","Inclusion Criteria:\n\n* Female and male patients diagnosed with cancer and planned to receive an anthracycline- or platinum- containing chemotherapy regimen.\n* ≥18 years of age.\n* Life expectancy \\> 6 months\n* Able to provide informed consent.\n* Patients must agree to complete and be able to complete the questionnaires and computerized assessments used to measure functional outcomes. Note: Patients who have visual impairment or have degenerative conditions (e.g. Parkinsons's disease, etc.) can participate if they cannot complete computerized assessments, as long as they can still complete the questionnaires with assistance.\n\nExclusion Criteria:\n\n* Presence of primary brain tumors or brain metastases.\n* Receive a primary chemotherapy regimen that does not include anthracycline- or platinum- containing chemotherapy.\n* Unwilling to undergo neuropsychological assessments necessary for the study.\n* Patients who are breastfeeding, pregnant or are planning to get pregnant during the study period. POCBP must have a negative pregnancy test at screening if there is suspicion of pregnancy. Patients who are considered not to be of childbearing potential must have a history of being postmenopausal (with a minimum of 1 year without menses), tubal ligation, or hysterectomy.\n* History of or suspected hypersensitivity to riluzole or to any of its excipients.\n* Patients taking or planned to take medications\u002Fsubstances with potential drug-drug interactions: pixantrone, current smoker (defined as having smoked within the last month), abametapir, cannabis, capmatinib, lapatinib, methotrexate, and levoketoconazole.\n* Hepatic impairment as indicated by: AST and\u002For ALT ≥ 3 X upper limit normal (ULN).\n* Have serious pre-existing medical conditions that, in the judgment of the investigator, would preclude participation in this study.",{"count":109,"type":21},[85],"This is a phase II single-arm, Phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining efficacy of riluzole in preventing cognitive dysfunction in subjects with cancer, who are receiving chemotherapy.",[25,227,689,26,32,167,229,230,29,28],"Gastric (Stomach) Cancer","2026-02-25",{"date":668,"type":43},{"date":693,"type":43},"2025-12-23",{"date":695,"type":21},"2028-12-31",{"name":248,"class":50}]